Skip to main content
Targeted SNCA Downregulation for Parkinson’s and Synucleinopathies

Targeted SNCA Downregulation for Parkinson’s and Synucleinopathies

Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting approximately 10 million people globally and 1 million in the U.S. The disease is characterized by involuntary movements such as tremors, stiffness,…

Read More

Novel Self-Assembling Nanoparticles for Extended Duration Local Anesthetics

Novel Self-Assembling Nanoparticles for Extended Duration Local Anesthetics

Unmet Need An estimated 40 million surgeries are performed every year in the United States. Out of this population, an estimated 80% had post-operative pain with 75% reporting it as moderate to extreme. Local anesthetics…

Read More

Flexible needle for targeted delivery of chronic pain treatment

Flexible needle for targeted delivery of chronic pain treatment

Unmet Need For patients suffering from chronic pain associated with degenerative changes, inflammation, neuropathy or cancer, the ability to carry out daily life and work activities is a challenge. Current treatment methods are limited and…

Read More

An injectable hydrogel scaffold that delivers gene therapies locally

An injectable hydrogel scaffold that delivers gene therapies locally

Unmet Need Gene therapy has applications ranging from tissue engineering to vaccine development to infectious disease. Most approaches to deliver nucleic material involve the systemic intravenous delivery of condensed nucleic acid (e.g., within a virus…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us